The Hippo Signaling Pathway as a Drug Target in Familial Dilated Cardiomyopathy

Area of Science:

• Cardiovascular Biology
• Molecular Cell Biology
• Mechanobiology

Background:

• The Hippo pathway is a critical regulator of organ size and cellular homeostasis.
• It senses the mechanical micro-environment of cardiac myocytes, influencing heart development, remodeling, and function.
• Dysregulation of the Hippo pathway is implicated in cardiac pathologies.

Purpose of the Study:

• To explore the role of the Hippo pathway in sensing and modulating the mechanical state of the adult heart.
• To discuss the involvement of Hippo signaling in familial dilated cardiomyopathy (DCM) triggered by sarcomere protein variants.
• To highlight the therapeutic potential of targeting the Hippo pathway for DCM treatment.

Main Methods:

• Review of existing literature on Hippo signaling in cardiac mechanics and disease.
• Analysis of the molecular mechanisms linking sarcomere mutations to Hippo pathway activation in DCM.
• Discussion of emerging small molecule therapeutics targeting the Hippo pathway for cardiac applications.

Main Results:

• The Hippo pathway acts as a key sensor of mechanical stress within cardiac myocytes.
• Mutations in sarcomere proteins can disrupt cardiac mechanics, leading to Hippo pathway dysregulation and familial DCM.
• Small molecules targeting the Hippo pathway show promise for novel DCM therapies.

Conclusions:

• Understanding cell-specific Hippo signaling in the cardiac micro-environment is essential for developing effective DCM therapies.
• Targeting the Hippo pathway represents a promising therapeutic strategy for dilated cardiomyopathy.
• Further research is needed to fully elucidate the therapeutic potential of Hippo pathway modulation in cardiac disorders.